A Study to Evaluate the Long-Term Safety and Effectiveness of Caplacizumab for Patients who Completed Study ALX0681-C301


About this study

The purpose of this study is to evaluate the long-term and repeated use safety and effectiveness of caplacizumab in patients who completed previous study ALX0681-C301.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Completed the Final (28 day) FU visit in Study ALX0681-C301
  • Is ≥18 years of age at the time of signing the informed consent form (ICF)
  • Provided informed consent prior to initiation of any study specific activity/procedure
  • Others as defined in the protocol

Exclusion Criteria

  • Not being able/willing to comply with the study protocol procedures
  • Currently enrolled in a clinical study with another investigational drug or device
  • Others as defined in the protocol

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Ronald Go, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer